NCT00026221 2016-03-17
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
8 trialsNCT00002767 2014-01-06
Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00002892 2013-12-19
Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00026520 2013-06-24
Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00026143 2013-06-05
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00004244 2013-03-21
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002763 2011-11-16
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00006385 2011-11-08
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed